Brief: Icosavax Announces Results From IVX-411 Drug Product Investigation

Icosavax

28/07/2022 22:58

July 28 (Reuters) - Icosavax Inc  ICVX.O :
    * ICOSAVAX ANNOUNCES RESULTS FROM IVX-411 DRUG PRODUCT
INVESTIGATION AND OUTLINES ADDITIONAL CORPORATE MILESTONES
    * ICOSAVAX INC - ANTIGEN COMPONENT OF IVX-411 FOUND TO BE
UNSTABLE; ISSUE SPECIFIC TO MOLECULE, NO EVIDENCE OF
READ-THROUGH TO OTHER ICOSAVAX PROGRAMS
    * ICOSAVAX INC - RESULTS OF INVESTIGATION CONFIRMED
COMPANY'S
INITIAL HYPOTHESIS THAT REDUCED POTENCY OBSERVED FOR IVX-411 WAS
ANTIGEN-SPECIFIC
    * ICOSAVAX INC - DATA TO DATE INDICATE THAT THIS ANTIGENIC
INSTABILITY IS NOT OBSERVED IN OTHER ICOSAVAX VACCINE
CANDIDATES, INCLUDING FOR RSV AND HMPV

Source text for Eikon:  ID:nGNX1McLZk 
Further company coverage:  ICVX.O 

 ((Reuters.Briefs@thomsonreuters.com;))